04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
00:34 , Nov 21, 2018 |  BC Extra  |  Company News

Deal with Idorsia gives Santhera shot at second DMD candidate

In a deal that will make Idorsia Ltd. (SIX:IDIA) its largest shareholder, Santhera Pharmaceuticals Holding AG (SIX:SANN) gained an option to exclusively in-license a second Duchenne muscular dystrophy candidate: vamorolone (VBP15). Santhera CEO Thomas Meier...
18:21 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers; other

TECHNOLOGY: Tissue markers; computational models A computational model based on urine levels of 10 mRNA splice variants could help diagnose DM1. Transcriptomic analysis of cell-free RNA in urine samples from 36 DM1 patients, 28 healthy...
18:10 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
12:15 , Oct 12, 2018 |  BC Extra  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
22:56 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Reata's CKD candidate improves kidney function in IgA nephropathy, diabetes cohorts

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from the IgA nephropathy and chronic kidney disease (CKD) associated with Type I diabetes cohorts of the open-label, U.S. Phase II PHOENIX trial of bardoxolone methyl to treat rare...
16:18 , Oct 4, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Bioinformatics screens; cellular assays; gene profiling A single-cell, sequencing-based method that correlates RNA expression with chromatin accessibility could help identify biomarkers of cellular activity and/or cell type. The method involves: distributing extracted cell nuclei...
19:34 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest inhibiting NFKB2 in combination with radiotherapy could help treat cancer. In glioblastoma patients treated with radiotherapy, high postmortem levels of NFKB2 mRNA in brain...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25...
22:30 , Jul 23, 2018 |  BC Extra  |  Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...